NEXGEL, Inc.

NasdaqCM NXGL

NEXGEL, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -3.60 M

NEXGEL, Inc. Operating Cash Flow is USD -3.60 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -9.01% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

NEXGEL, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3.30 M, a 6.84% change year over year.
NEXGEL, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -3.54 M, a -78.88% change year over year.
NEXGEL, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.98 M, a -12.12% change year over year.
NEXGEL, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.76 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: NXGL

NEXGEL, Inc.

CEO	Mr. Adam R. Levy
IPO Date	Dec. 22, 2021
Location	United States
Headquarters	2150 Cabot Boulevard West
Employees	19
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Cosmetics

Description

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.

Key trends

Past 5 years